Aeolus Pharmaceuticals Inc (AOLS) financial statements (2022 and earlier)

Company profile

Business Address 26361 CROWN VALLEY PARKWAY, SUITE 150
MISSION VIEJO, CA 92691
State of Incorp. DE
Fiscal Year End September 30
SIC 2834 - Pharmaceutical Preparations (benchmarking)
More info Complete financial analysis Financial benchmarking

Balance sheet (Statement of financial position) ($ in thousands)

9/30/2016
9/30/2015
9/30/2014
9/30/2013
9/30/2012
ASSETS
Current Assets
Cash, cash equivalents, and short-term investments3,155941,517869281
Cash and cash equivalents3,155941,517869281
Receivables7501,5851,559370882
Prepaid expense and other current assets61
Other undisclosed current assets23066472696 
Total current assets:4,1351,7453,5481,9351,224
Noncurrent Assets
Long-term investments and receivables3232323291
Long-term investments3232323291
Deferred costs 21426656 
Other undisclosed noncurrent assets (21)(426)(657)(59)
Total noncurrent assets:3232323132
TOTAL ASSETS:4,1671,7773,5801,9661,256
LIABILITIES AND EQUITY
Liabilities
Current Liabilities
Accounts payable and accrued liabilities, including:9721,5981,5525792,272
Other undisclosed accounts payable and accrued liabilities9721,5981,5525792,272
Debt 727   
Deferred revenue and credits 22443682 
Other undisclosed current liabilities 275   
Total current liabilities:9722,6221,9951,2612,272
Noncurrent Liabilities
Other undisclosed noncurrent liabilities    19,319
Total noncurrent liabilities:    19,319
Total liabilities:9722,6221,9951,26121,591
Stockholders' equity
Stockholders' equity attributable to parent, including:3,195(845)1,585705(20,335)
Preferred stock 5555
Common stock1,5201,3591,3591,346627
Additional paid in capital191,863184,421184,223183,276159,747
Accumulated deficit(190,188)(186,630)(184,002)(183,922)(180,714)
Warrants and rights outstanding 275  19,319
Other undisclosed stockholders' equity attributable to parent (275)  (19,319)
Total stockholders' equity:3,195(845)1,585705(20,335)
TOTAL LIABILITIES AND EQUITY:4,1671,7773,5801,9661,256

Income statement (P&L) ($ in thousands)

9/30/2016
9/30/2015
9/30/2014
9/30/2013
9/30/2012
Revenues
(Revenue, Net)
2,0763,1119,6313,9287,293
Cost of revenue   (555) 
Gross profit:2,0763,1119,6313,3737,293
Operating expenses(5,349)(6,142)(9,941)(6,071)(9,664)
Other undisclosed operating income 405230  
Operating loss:(3,273)(2,626)(80)(2,698)(2,371)
Interest and debt expense(285)(2)   
Loss from continuing operations before income taxes:(3,558)(2,628)(80)(2,698)(2,371)
Income tax expense (2)(2)(2)(2)
Net loss:(3,558)(2,630)(82)(2,700)(2,373)
Other undisclosed net income (loss) attributable to parent 22(508)4,071
Net income (loss) attributable to parent:(3,558)(2,628)(80)(3,208)1,698
Other undisclosed net loss available to common stockholders, basic(2,486)    
Net income (loss) available to common stockholders, diluted:(6,044)(2,628)(80)(3,208)1,698

Comprehensive Income ($ in thousands)

9/30/2016
9/30/2015
9/30/2014
9/30/2013
9/30/2012
Net loss:(3,558)(2,630)(82)(2,700)(2,373)
Comprehensive loss, net of tax, attributable to parent:(3,558)(2,630)(82)(2,700)(2,373)

Statements sources

The financial statements are based on the company's filings with the The U.S. Securities and Exchange Commission (SEC) through the Electronic Data Gathering, Analysis, and Retrieval system (EDGAR). The information is derived from the 10-K and 10-Q reports submitted to the SEC in XBRL (eXtensible Business Reporting Language) format and presented according to the US GAAP Taxonomy. Please review the original filings for a more detailed information.

Login to ReadyRatios

 

Have you forgotten your password?

Are you a new user?

Login As
You can log in if you are registered at one of these services: